about
Modulation of the Rho/ROCK pathway in heart and lung after thorax irradiation reveals targets to improve normal tissue toxicity.The treatment of patients with 1-3 brain metastases: is there a place for whole brain radiotherapy alone, yet? A retrospective analysis.Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.Radiotherapy for adult medulloblastoma: Long term result from a single institution. A review of prognostic factors and why we do need a multi-institutional cooperative programResected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy.Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial.Transdermal buprenorphine for oropharyngeal mucositis-associated pain in patients treated with radiotherapy for head and neck cancer.Circulating tumour cells in locally advanced head and neck cancer: preliminary report about their possible role in predicting response to non-surgical treatment and survival.Could machine learning improve the prediction of pelvic nodal status of prostate cancer patients? Preliminary results of a pilot study.An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.Salvage Low Dose Rate Brachytherapy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes.Three-dimensional conformal radiotherapy, static intensity-modulated and helical intensity-modulated radiotherapy in glioblastoma. Dosimetric comparison in patients with overlap between target volumes and organs at risk.Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines.Light and shadows of a new technique: is photon total-skin irradiation using helical IMRT feasible, less complex and as toxic as the electrons one?Clinical outcomes and toxicity after exclusive versus postoperative radiotherapy in supraglottic cancer: new solutions for old problems? The case of stage III and IV diseaseClinical outcomes and toxicity after exclusive versus postoperative radiotherapy in supraglottic cancer: new solutions for old problems? The case of stage I and II diseaseA benchmark study on 883 nasopharyngeal cancer patients treated in two Italian Centres from 1977 to 2000. Part I: evolving technical choices and survivalA benchmark study on 883 nasopharyngeal cancer patients treated in two Italian Centres from 1977 to 2000. Part II: evolving technical choices and toxicity patternsA national multicenter study on 1072 DCIS patients treated with breast-conserving surgery and whole breast radiotherapy (COBCG-01 study)Overexpression of sialidase NEU3 increases the cellular radioresistance potential of U87MG glioblastoma cellsExploring the Role of Enzalutamide in Combination with Radiation Therapy: An In Vitro StudyStereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort studyLong-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving SurgeryApplying radiation protection and safety in radiotherapy
P50
Q30484563-7D101FF5-4703-4BFA-A15D-3C0A3DEDEF65Q35616014-6B7FE9D2-4614-49E0-A90D-4189A7BC2C20Q38383388-A7E6711F-2852-4DF5-A754-EA8B94B0FB64Q38537549-2BBF970A-9C4F-410B-9324-9F4452292380Q39732809-9F27AD2D-EB59-4257-A4BF-551B61B32220Q41068116-8F3012B3-A4E2-4D1E-BBF2-E4C01A4450E3Q43127876-9F53E26E-4430-49A6-B7E9-98ED87367A93Q45844676-F4C10ED0-2849-4CA1-978A-CD440C8EAA66Q45954421-51287CFF-95C5-4914-A6A6-BD884DFFB264Q46799959-FB0C6AFC-DAE8-49BF-B801-395B94CFD47AQ47099465-37BEA475-7286-4511-8428-C0B467A94382Q48629409-4BE4B83F-1993-48E5-8021-A8BF6CBF20C8Q51031963-94C7253D-A2F5-4342-B0F1-A2E79FE4C788Q52788391-0CCFD4C5-EAFC-4B13-802C-6BE04942E93CQ58696459-AAAD6C6C-ED3C-4BB2-9FD9-C2B7C24AF773Q60547803-86898F47-9F09-4A2A-AC93-419290F316D7Q60547823-761DAB75-4048-444F-8D05-F4B7461D4E51Q60547871-B018D98E-DF68-4F2D-B617-864009CA4D7BQ60547873-B2BE2ECF-DF6D-48AA-AB39-B6A3651F6291Q62693648-B2EEA149-BB9D-4AB8-85E3-0A8762681F0CQ64388773-6ADFD397-D8B4-4821-B3F9-AEAC08DC5DDAQ88923645-54253BD6-9DBD-4D39-8E0C-806513F06564Q90748402-BF6BE81D-5769-478E-A7A0-C21267CEE5F2Q91266225-7962305F-DB0D-4762-9DBC-04B51B5B30BFQ92139552-114D1EC3-FE05-463F-A45C-195133E6E67A
P50
description
investigador
@es
researcher
@en
name
Nadia Pasinetti
@en
type
label
Nadia Pasinetti
@en
prefLabel
Nadia Pasinetti
@en
P31
P496
0000-0002-2715-1840